Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
HORSHOLM, Denmark, May 15, 2013 /PRNewswire/ --
Highlights:
•On 29 April, 2013 Veloxis submitted the MAA to the European Medicines Agency (EMA) seeking approval to market LCP-Tacro™ for the prevention of organ rejection in kidney transplant patients in the European Union. The MAA submission is based on the favorable results of the LCP-Tacro™ Phase III 3001 study in stable kidney transplant patients and data from an extensive Phase I and II clinical program. Veloxis expects the decision from the European Union in 2014.
Help employers find you! Check out all the jobs and post your resume.
HORSHOLM, Denmark, May 15, 2013 /PRNewswire/ --
Highlights:
•On 29 April, 2013 Veloxis submitted the MAA to the European Medicines Agency (EMA) seeking approval to market LCP-Tacro™ for the prevention of organ rejection in kidney transplant patients in the European Union. The MAA submission is based on the favorable results of the LCP-Tacro™ Phase III 3001 study in stable kidney transplant patients and data from an extensive Phase I and II clinical program. Veloxis expects the decision from the European Union in 2014.
Help employers find you! Check out all the jobs and post your resume.
